Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 16/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19264305 | 0.84 | TNK2 (0.46) | TNK2FGFR1FGFR2 | |
| SCHEMBL398410 | 0.83 | TNK2 (0.34) | TNK2FGFR1FGFR2 | |
| SCHEMBL594589 | 0.83 | TNK2 (0.34) | TNK2FGFR1FGFR2 | |
| SCHEMBL14536935 | 0.83 | TNK2 (0.34) | TNK2FGFR1 | |
| SCHEMBL19264180 | 0.78 | TNK2 (0.46) | TNK2 | |
| SCHEMBL14948254 | 0.78 | TNK2 (0.48) | TNK2FGFR1 | |
| SCHEMBL19264027 | 0.76 | TNK2 (0.46) | TNK2FGFR1 | |
| SCHEMBL1129184 | 0.76 | TNK2 (0.43) | TNK2 | |
| SCHEMBL19264282 | 0.76 | TNK2 (0.50) | TNK2 | |
| SCHEMBL19264066 | 0.76 | TNK2 (0.39) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20130123501-A1 | PROCESS FOR THE PREPARATION OF THE COMPOUND OSI-906 | OSI Pharmaceuticals, LLC | 2013-05-16 | — | — | US | disclosed |
| WO-2007106503-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070129547-A1 | Process to prepare substituted imidazopyrazine compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007061737-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129547-A1 | Process to prepare substituted imidazopyrazine compounds | ZYX, BRPF3, NBAS | TNK2 1322/4885FGFR1 1456/4885FGFR2 2259/4885 |
| US-20130123501-A1 | PROCESS FOR THE PREPARATION OF THE COMPOUND OSI-906 | ABL1, ERBB2, ALK | TNK2 427/4885FGFR1 237/4885FGFR2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.